Analyzing Oculis (OCS) and Its Competitors

Oculis (NASDAQ:OCS) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Oculis to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.

Risk & Volatility

Oculis has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Oculis’ peers have a beta of -3.81, suggesting that their average stock price is 481% less volatile than the S&P 500.

Valuation and Earnings

This table compares Oculis and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oculis	$1.45 million	-$119.44 million	-4.56
Oculis Competitors	$3.57 billion	$3.20 billion	552.49

Oculis’ peers have higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Oculis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-8,613.92%	-39.24%	-33.45%
Oculis Competitors	-2,380.61%	-219.90%	-15.56%

Institutional and Insider Ownership

22.3% of Oculis shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Oculis and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1	0	8	0	2.78
Oculis Competitors	7776	13772	25741	1037	2.41

Oculis presently has a consensus price target of $37.38, suggesting a potential upside of 379.78%. As a group, “Pharmaceuticals” companies have a potential upside of 24.84%. Given Oculis’ stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than its peers.

Summary

Oculis peers beat Oculis on 8 of the 13 factors compared.

Oculis Company Profile

Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.